FDA Commissioner Kessler Resigns His Post

2 December 1996

US Food and Drug Administration Commissioner David Kessler announced his proposed resignation on Monday, November 25. He will leave the agency early 1997, after a successor has been named. In the interim, the agency has admittted there will be a "lame duck" Commissioner.

In an interview with ABC News after announcing his resignation, Dr Kessler said that he was leaving because "there was a time to serve and a time to leave." He said that he had focused on the things that made a difference in the daily lives of Americans - on diet and health, on food labeling and on tobacco. As for whether he was satisfied with his accomplishments, he said, "you can't do everything."

Proud Of Cutting Drug Approval Times Dr Kessler said he was proud of the cut in approval times for drugs, noting that all nine AIDS drugs now in use were approved first in the USA. The USA, he added, has a faster approval time than other countries. Asked if his resignation would mean radical change at the agency, he stated that the FDA cannot be deregulated if health and safety are to remain at the forefront.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight